Protocol Ledger

NCT03943147 · Phase II · TERMINATED

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Interventional Phase II clinical trial protocol NCT03943147 sponsored by Bristol Myers Squibb in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-15 Enrollment: 16 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03943147
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03943147
Protocol FieldVerified Registry Value
NCT IdentifierNCT03943147
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment16 participants (ACTUAL)
Registered Start Date2019-07-15
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI